Context: Our previous case-control study identified human neutrophil peptide (HNP) as a potential biomarker for bronchiolitis obliterans syndrome (BOS) in lung transplant recipients. Objective: To prospectively validate HNP as a biomarker for BOS. Materials and methods: HNP was measured by ELISA in bronchoalveolar lavage (BAL) fluid in lung transplant recipients. Results: The first HNP measurement after reaching baseline pulmonary function was predictive of developing BOS ≥2 (p=0.0419). HNP remained elevated in those that developed BOS. The effect of potential confounders did not significantly impact BOS-free survival time. Conclusion: HNP levels are elevated early and persistently in those that develop BOS.
Bibliographical noteFunding Information:
This work was supported by the National Institutes of Health [Grants HL080041, HL07741] Work performed at the University of Minnesota.
- Lung transplant